



Technology Pipeline

# CELL & GENE THERAPY

 **Innovations**  
UNIVERSITY OF COLORADO  
ANSCHUTZ MEDICAL CAMPUS



 *New Target*
 *Platform Tech*
 *Regenerative Medicine*

  **AVAILABLE**
  **PARTNERED**



## Advancing to the Clinic

*The Gates Institute is partnering with CU Anschutz researchers to de-risk and translate these groundbreaking cell and gene therapies from development into Phase 1 first-in-human clinical trials.*

PRINCIPAL INVESTIGATOR (PI)

Terry Fry	1922	19X22 CAR FOR ADULT AND PEDS LYMPHOMA	
Val Canto-Soler	4705	RETINAL TRANSPLANT FOR AMD	
Eduardo Davila	5492	ENGINEERED TILS FOR SOLID TUMORS (PARTNERED)	
M. Eric Kohler	6343	CAR FOR R/R AML	
Sujatha Venkataraman	6133	LOGIC-GATED CAR-T FOR BRAIN TUMORS	
Michael Verneris	5508	HOMING OF B7H3 CAR THERAPY FOR SOLID TUMORS	
M. Eric Kohler	5685	CAR CONSTRUCT FOR LOW ANTIGEN CANCERS	
Bilousova and Kogut	3555	iPSC REPROGRAMMING AND GENE-CORRECTION FOR EB	



## About our partners

# GATES INSTITUTE

Gates Institute is a world-class translational research institute with cell/gene and biologics cGMP manufacturing capabilities. Based at the University of Colorado Anschutz Medical Campus, it is part of a rich biomedical ecosystem, enabling the translation of life saving treatments for a host of adult and pediatric diseases at unmatched speed and scope. They bring together and support researchers and clinicians who specialize in regenerative, cell/gene, and biologics therapies, accelerating discoveries from concept to cures.

The state-of-the-art Gates Biomanufacturing Facility is an FDA-compliant cGMP facility with 21,000 square feet of manufacturing, laboratory, warehouse, and administrative space. Its unique positioning within the Fitzsimons Innovation Community enables partnerships with both campus researchers and industry biotechnology companies. The facility excels to facilitate process development, scale up, and GMP manufacture for human use, materials management, product quality control, and IND submissions.

In addition, Gates Institute is committed to continuing to grow the cell therapy ecosystem at CU Anschutz. To date, the Gates Grubstake Fund has supported over 29 research projects with nearly \$10MM in funding.

For more information, visit [www.gates.cuanschutz.edu](http://www.gates.cuanschutz.edu) and [www.gatesbiomanufacturing.com](http://www.gatesbiomanufacturing.com)







**Where we are located**

# CU ANSCHUTZ MEDICAL CAMPUS

The University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes, and two nationally ranked independent hospitals - UCHealth University of Colorado Hospital and Children's Hospital Colorado - that treat more than two million adult and pediatric patients each year. Innovative, interconnected and highly collaborative, the University of Colorado Anschutz Medical Campus delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by over \$704 million in research grants.

For more information, visit [www.cuanschutz.edu](http://www.cuanschutz.edu).



*New Target*
*Platform Tech*
*Regenerative Medicine*

  **AVAILABLE**
  **PARTNERED**




## Immunology

<b>Brian Freed</b>	5637	HLA GENE EDITING FOR AUTOIMMUNE DISEASE	<span style="background-color: #d9d9d9; width: 100%; height: 15px;"></span>
<b>Terry Fry</b>	5905	BAIT CAR FOR AUTOIMMUNE DISEASE	<span style="background-color: #c49a3d; width: 80%; height: 15px;"></span>
<b>Michael Verneris</b>	5426	INNATE LYMPHOID CELL THERAPY	<span style="background-color: #c49a3d; width: 85%; height: 15px;"></span>

## Cardiology

<b>Kunhua Song</b>	4946	GENE THERAPY FOR DANON DISEASE	
<b>Kunhua Song</b>	3770	REGENERATION OF CARDIOMYOCYTES	
<b>Jeff Jacot</b>	4987	AMIINOCYTE-DERIVED HEART PATCH	

PRINCIPAL INVESTIGATOR (PI)



## About us

# CU INNOVATIONS

We bring together industry partners, entrepreneurs, and investors to help CU Researchers create biomedical technology that improves the quality of life worldwide. With expertise in patents, copyrights, and licensing, CU Innovations translates discovery into impact through transparent, flexible, best practice intellectual property management services.

Located on the University of Colorado Anschutz Medical Campus, CU Innovations provides access to an extensive portfolio of biomedical technologies, clinical validation opportunities, and resources for startup development.

Let's start a conversation.



### CONTACT

Doreen Molk, MS  
Senior Licensing Manager, CU Innovations  
University of Colorado Anschutz Medical Campus  
[doreen.molk@cuanschutz.edu](mailto:doreen.molk@cuanschutz.edu)



## Innovations

UNIVERSITY OF COLORADO  
ANSCHUTZ MEDICAL CAMPUS

Anschutz Health Sciences Building  
1890 N. Revere Ct., Suite 6202  
Aurora, CO 80045

(303) 724 - 3720  
[cuinnovations@cuanschutz.edu](mailto:cuinnovations@cuanschutz.edu)

 /company/cu-innovations

 @CUInnovations



**WEBSITE** Scan to view our website and to learn more about how we can best support you > [cuanschutz.edu/cu-innovations](https://cuanschutz.edu/cu-innovations)

